Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy - Trial NCT06422247
Access comprehensive clinical trial information for NCT06422247 through Pure Global AI's free database. This phase not specified trial is sponsored by Bristol-Myers Squibb and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Bristol-Myers Squibb
Timeline & Enrollment
N/A
Jun 14, 2024
Apr 30, 2025
Primary Outcome
Overall survival (OS)
Summary
The purpose of this study is to describe the therapeutic practices and the prognosis of
 patients with relapsed or refractory peripheral T-cell lymphoma in Japan
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06422247
Non-Device Trial